The 10 most recent market catalysts affecting $GOSS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 11, 2026
Corporate Catalyst
Bearish
Impact 85
Gossamer Bio shares are trading lower after the company announced it filed a Certificate of Amendment in Delaware to effect its 1‑for‑80 reverse stock split and reduce authorized shares, effective September 10.
The 1-for-80 reverse stock split for Gossamer Bio (GOSS) is a highly negative corporate action, typically undertaken by companies whose stock price has fallen to dangerously low le…
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 75
Gossamer Bio To Effect 1-For-80 Reverse Stock Split
A 1-for-80 reverse stock split for Gossamer Bio (GOSS) is a strong indicator of the company's struggle to maintain its share price above minimum exchange requirements, typically $1…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 85
Gossamer Bio shares are trading lower after the company announced a 1-for-80 reverse stock split
A 1-for-80 reverse stock split is an extreme measure, indicating Gossamer Bio is likely facing delisting from its exchange due to a low share price. While it artificially boosts th…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 75
Gossamer Bio Announces 1-For-80 Reverse Stock Split, Effective September 10
Gossamer Bio is implementing a 1-for-80 reverse stock split, effective September 10, 2026, to meet the Nasdaq Global Select Market's minimum bid price requirement. This action is a…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 85
Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones
Gossamer Bio has secured a structured private placement offering up to $250 million, which is crucial for funding its lead drug candidate, seralutinib, through the FDA approval pat…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 75
Gossamer Bio shares are trading higher after the company announced that it has entered into a securities purchase agreement for a private placement financing to provide up to $250 million in aggregate gross proceeds.
This private placement is a significant positive catalyst for Gossamer Bio, providing crucial capital for a biotechnology company often reliant on external funding for R&D and clin…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 85
Gossamer Bio Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $9.238M Beat $5.193M Estimate
Gossamer Bio announced its Q2 earnings, reporting a loss of $(0.08) per share, which was a 33.33% beat against the analyst consensus of $(0.12). Additionally, the company's sales o…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 55
Leerink Partners Upgrades Gossamer Bio to Outperform, Maintains Price Target to $1
Leerink Partners analyst Joseph Schwartz upgraded Gossamer Bio (GOSS) from Market Perform to Outperform, while keeping the price target at $1. This upgrade indicates a more favorab…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 85
Gossamer Bio shares are trading higher after a pre‑NDA meeting and FDA minutes outlined a path to a September 2026 NDA filing for seralutinib in PAH. The company also regained global rights to the drug and won shareholder approval for a note exchange and reverse split to bolster its capital structure.
This headline is a major positive catalyst for Gossamer Bio. The outlined path to a September 2026 NDA filing for seralutinib in PAH provides much-needed clarity and de-risks the d…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 85
Gossamer Bio Advances Seralutinib Toward NDA In September 2026, Reacquires Global Rights To Seralutinib From Chiesi
Gossamer Bio has provided a definitive timeline for its lead drug candidate, seralutinib, with an NDA submission targeted for September 2026. This clarity, combined with the reacqu…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.